Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Unknown 10Completed 7Recruiting 4Withdrawn 3Not yet recruiting 2Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × Folfox protocol × Clear all
NCT02527772 2019-06-04

LD-FOX4/HCC

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT02534337 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03803254 2019-05-06

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡